SPY444.28+6.42 1.47%
DIA348.27+5.77 1.68%
IXIC15,061.14+164.30 1.10%

BRIEF-Rigel Pharmaceuticals Publishes Data From Phase 2 Trial Of Fostamatinib In Hospitalized Covid-19 Patients

reuters.com · 09/01/2021 07:49
BRIEF-Rigel Pharmaceuticals Publishes Data From Phase 2 Trial Of Fostamatinib In Hospitalized Covid-19 Patients

- Rigel Pharmaceuticals Inc RIGL:

  • DATA FROM NIH/NHLBI-SPONSORED PHASE 2 TRIAL OF FOSTAMATINIB IN HOSPITALIZED COVID-19 PATIENTS PUBLISHED IN CLINICAL INFECTIOUS DISEASES

  • RIGEL PHARMACEUTICALS INC - FOSTAMATINIB DEMONSTRATED A CONSISTENTLY WELL-TOLERATED SAFETY PROFILE FOR HOSPITALIZED PATIENTS WITH COVID-19

Source text for Eikon: ID:nPn3rJZ7Za

Further company coverage: RIGL


((Reuters.Briefs@thomsonreuters.com;))